Plastic Surgery Addiction in Patients With Body Dysmorphic Disorder

by Eda Gorbis, Ph.D., M.F.C.C., and Yelena Kholodenko

Definition of the ideal body changes over time and across cultures. In the 18th century, full-figured women were considered attractive. Today, a woman with a slim, long-legged figure is the token of beauty. In different cultures, different shapes of women are in style. However, for people with body dysmorphic disorder (BDD), appearance is not simply a matter of style. According to the *DSM-IV*, people with BDD have a pervasive distortion of their self-image and a persistent preoccupation with a particular part of their body or overall appearance.

When Body Image Becomes a Disorder

Body dysmorphic disorder is also known as *dysmorphophobia*. It manifests itself as an abnormal dissatisfaction with one's physical appearance and concerns with one's appearance from three to eight hours a day (Phillips, 2001). Of Americans, 30% to 40% have minor concerns with their appearances (Watkins, 2004). However, those minor concerns are transient and do not interfere with their functioning or social/occupational performance. In the United States, BDD affects about 2% of the population (Phillips, 2001), which is equivalent to 5 million Americans and strikes males and females equally (Phillips and Diaz, 1997). In one study, the onset occurred before age 18 in about 70% of the cases (Albertini and Phillips, 1999). People with BDD often change their social and professional lifestyles to avoid appearing in public and spend excessive time trying to look presentable (Phillips and Castle, 2001).

Surgery and Dermatological Treatment: Signs of the Disease

It is estimated that about 50% of BDD sufferers seek some sort of the professional medical help in the form of plastic surgery or dermatological treatment (Phillips et al., 1993). In one study, out of 268 patients presenting for dermatological treatment, 11.9% screened for BDD (Phillips et al., 2000). In another study of 289 people (250 adults and 39 children) who met *DSM-IV* diagnostic criteria for BDD, 76.4% of them were looking for nonpsychiatric treatment and 66.0% of adults received it (Phillips et al., 2001). Because BDD is not typically recognized by plastic surgeons and general practitioners, these patients can undergo a succession of invasive procedures. Veale (2000) reported on 25 patients with BDD who had undergone a total of 46 cosmetic procedures before they were diagnosed with BDD. The same article indicated that nine of those 25 patients had performed self-surgery.

Plastic surgery provides no benefit for patients with BDD because it is never good enough, and the obsession persists. In all cases obsession might move from one body part to another. Surgeries and dermatological treatments rarely to almost never improve BDD symptoms and oftentimes worsen them (American Society for Dermatologic Surgery, undated). Another study showed that a majority of the BDD sufferers received nonpsychiatric treatments, but responded poorly to them (Phillips and Castle, 2001; Phillips et al., 1993). About 63% of patients get treatment in both surgery and dermatology. In a survey of cosmetic surgeons, 7% replied that patients with BDD stop requesting surgery after one procedure, 13% that they stop sometimes, and 63% of cosmetic surgeons replied that patients with BDD continue asking for repeated surgeries (Knorr et al., 1967).

(Please see Plastic Surgery Addiction, *page 80)*

BRIEF SUMMARY. See package insert for full prescribing information.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. GEODON (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis.

INDICATIONS—GEODON Capsules is indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder with or without psychotic features. GEODON® (ziprasidone mesylate) for Injection is indicated for acute agitation in schizophrenic patients.

CONTRAINDICATIONS —*QT Prolongation:* Because of GEODON's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, GEODON is contraindicated in patients with a known history of QT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see **WARNINGS**). Pharmacokinetic/pharmacodynamic studies between GEODON and other drugs that prolong the QT interval have not been performed. An additive effect of GEODON and other drugs that prolong the QT interval cannot be excluded. Therefore, GEODON should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, or tacrolimus. GEODON is also contraindicated with drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning (see **WARNINGS**). GEODON is contraindicated in individuals with a known hypersensitivity to the product. **WARNINGS —Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. GEODON (ziprasidone) is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning). *QT Prolongation and Risk of Sudden Death:*** **GEODON use should be avoided in combination with other drugs that are known to prolong the QT_c interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QT_c interval. Such drugs should not be prescribed with GEODON. A study directly comparing the QT/QT_c-prolonging effect of GEODON with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in QT_c from baseline for GEODON ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. In this study, the effect of GEODON on QT_c length was not augmented by the presence of a metabolic inhibitor (ketoconazole 200 mg bid). In placebo-controlled trials, GEODON increased the QT_c interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials the electrocardiograms of 2/2988 (0.06%) GEODON patients and 1/440 (0.23%) placebo patients revealed QT_c intervals exceeding the potentially clinically relevant threshold of 500 msec. In the GEODON patients, neither case suggested a role of GEODON. Some drugs that prolong the QT/QT_c interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QT_c prolongations may also increase risk, or increase it in susceptible individuals, such as those with hypokalemia, hypomagnesemia, or genetic predisposition. Although torsade de pointes has not been observed in association with the use of GEODON at recommended doses in premarketing studies, experience is too limited to rule out an increased risk. A study evaluating the QT/QT_c prolonging effect of intramuscular GEODON, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of GEODON (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular GEODON is 50% higher than the recommended therapeutic dose. The mean change in QT_c from baseline was calculated for each drug using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QT_c from baseline for GEODON was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QT_c from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patient had a QT_c interval exceeding 500 msec. As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking GEODON at recommended doses. The premarketing experience for GEODON did not reveal an excess of mortality for GEODON compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, GEODON's larger prolongation of QT_c length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for GEODON than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QT_c interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QT_c interval; and (4) presence of congenital prolongation of the QT interval. GEODON should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias (see CONTRAINDICATIONS, and see *Drug Interactions* under PRECAUTIONS). It is recommended that patients being considered for GEODON treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during GEODON treatment. Persistently prolonged QT_c intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, GEODON should be avoided in patients with histories of significant cardiovascular illness, eg, QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. GEODON should be discontinued in patients who are found to have persistent QT_c measurements >500 msec. *Neuroleptic Malignant Syndrome (NMS):*** A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. ***Tardive Dyskinesia (TD):*** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of TD appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop TD. If signs and symptoms of TD appear in a patient on GEODON, drug discontinuation should be considered. ***Hyperglycemia and Diabetes Mellitus:*** Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. **PRECAUTIONS —*General:*** Rash: In premarketing trials, about 5% of GEODON patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was dose related, although the finding might also be explained by longer exposure in higher-dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly upon treatment with antihistamines or steroids and/or upon discontinuation of GEODON, and all patients were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, GEODON should be discontinued. Orthostatic Hypotension: GEODON may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α_1-adrenergic antagonist properties. Syncope was reported in 0.6% of GEODON patients. GEODON should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures: In clinical trials, seizures occurred in 0.4% of GEODON patients. There were confounding factors that may have contributed to seizures in many of these cases. As with other antipsychotic drugs, GEODON should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold. Hyperprolactinemia: As with other drugs that antagonize dopamine D_2 receptors, GEODON elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive and Motor Impairment: Somnolence was a commonly reported adverse event in GEODON patients. In the 4- and 6-week placebo-controlled trials, somnolence was reported in 14% of GEODON patients vs 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that GEODON therapy does not affect them adversely. Priapism: One case of priapism was reported in the premarketing database. Body Temperature Regulation: Although not reported with GEODON in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia, and GEODON and other antipsychotic drugs should be used cautiously in patients at risk. Suicide: The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. GEODON prescriptions should be written for the smallest quantity of capsules consistent with good patient management to reduce overdose risk. Use in Patients with Concomitant Illness: Clinical experience with GEODON in patients with certain concomitant systemic illnesses is limited. GEODON has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QT_c prolongation and orthostatic hypotension with GEODON, caution should be observed in cardiac patients (see ***QT Prolongation and Risk of Sudden Death*** in **WARNINGS** and Orthostatic Hypotension in **PRECAUTIONS**). ***Information for Patients:*** To ensure safe and effective use of GEODON, the information and instructions in the *Patient Information Section* should be discussed with patients. ***Laboratory Tests:*** Patients being considered for GEODON treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be repleted before treatment. Patients who are started on diuretics during GEODON therapy need periodic monitoring of serum potassium and magnesium. Discontinue GEODON in patients who are found to have persistent QT_c measurements >500 msec (see **WARNINGS**). ***Drug Interactions:*** (1) GEODON should not be used with any drug that prolongs the QT interval. (2) Given the primary CNS effects of GEODON, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, GEODON may enhance the effects of certain antihypertensive agents. (4) GEODON may antagonize the effects of levodopa and dopamine agonists. Effect of Other Drugs on GEODON: *Carbamazepine*, 200 mg bid for 21 days, resulted in a decrease of approximately 35% in the AUC of GEODON. *Ketoconazole*, a potent inhibitor of CYP3A4, 400 mg qd for 5 days, increased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg qd for 2 days, did not affect GEODON pharmacokinetics. Coadministration of 30 mL of *Maalox* did not affect GEODON pharmacokinetics. Population pharmacokinetic analysis of schizophrenic patients in controlled clinical trials has not revealed any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. Effect of GEODON on Other Drugs: In vitro studies revealed little potential for GEODON to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions with GEODON due to displacement. GEODON 40 mg bid administered concomitantly with *lithium* 450 mg bid for 7 days did not affect the steady-state level or renal clearance of lithium. GEODON 20 mg bid did not affect the pharmacokinetics of concomitantly administered *oral contraceptives*, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vitro results, a study in normal healthy volunteers showed that GEODON did not alter the metabolism of *dextromethorphan*, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio. ***Carcinogenesis, Mutagenesis, Impairment of Fertility:*** Lifetime carcinogenicity studies were conducted with GEODON in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice. GEODON had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hyperprolactinemia). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of *S. typhimurium* in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: GEODON increased time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m² basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m² basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m² basis). The fertility of female rats was reduced. ***Pregnancy—Pregnancy Category C:*** There are no adequate and well-controlled studies in pregnant women. GEODON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ***Labor and Delivery:*** The effect of GEODON on labor and delivery in humans is unknown. ***Nursing Mothers:*** It is not known whether, and if so in what amount, GEODON or its metabolites are excreted in human milk. It is recommended that women receiving GEODON should not breast feed. ***Pediatric Use:*** The safety and effectiveness of GEODON in pediatric patients have not been established. ***Geriatric Use:*** Of the approximately 4500 patients treated with GEODON in clinical studies, 2.4% (109) were 65 years of age or over. In general, there was no indication of any different tolerability for GEODON or of reduced clearance of GEODON in the elderly compared to younger adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to GEODON, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. **ADVERSE REACTIONS —*Adverse Findings Observed in Short-term, Placebo-Controlled Trials:*** The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. ***Adverse Events Associated with Discontinuation:*** Schizophrenia: Approximately 4.1% (29/702) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 2.2% (6/273) on placebo. The most common event associated with dropout was rash, including 7 dropouts for rash among GEODON patients (1%) compared to no placebo patients (see **PRECAUTIONS**). Bipolar Mania: Approximately 6.5% (18/279) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 3.7% (5/136) on placebo. The most common events associated with dropout in the GEODON-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash and vomiting, with 2 dropouts for each of these events among GEODON patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse events. ***Adverse Events at an Incidence ≥5% and at Least Twice the Rate of Placebo:*** The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (8%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31%), extrapyramidal symptoms (31%), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Body as a Whole—asthenia, accidental injury, chest pain. Cardiovascular—tachycardia. Digestive—nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous—extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory—respiratory tract infection, rhinitis, cough increased. Skin and Appendages—rash, fungal dermatitis. Special Senses—abnormal vision. Bipolar Mania: Body as a Whole—headache, asthenia, accidental injury. Cardiovascular—hypertension. Digestive—nausea, diarrhea, dry mouth, vomiting, increased salivation, tongue edema, dysphagia. Musculoskeletal—myalgia. Nervous—somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. Respiratory—pharyngitis, dyspnea. Skin and Appendages—fungal dermatitis. Special Senses—abnormal vision. ***Dose Dependency:*** An analysis for dose response in the schizophrenia trials revealed an apparent relation of adverse event to dose for the following: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. ***Extrapyramidal Symptoms (EPS):*** The incidence of reported EPS for GEODON patients in the short-term, placebo-controlled schizophrenia trials was 14% vs 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale and the Barnes Akathisia Scale did not generally show a difference between GEODON and placebo. ***Vital Sign Changes:*** GEODON is associated with orthostatic hypotension (see **PRECAUTIONS**). ***Weight Gain:*** In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of ≥7% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for GEODON patients (10%) vs placebo patients (4%). A median weight gain of 0.5 kg was observed in GEODON patients vs 0.0 kg in placebo patients. Weight gain was reported as an adverse event in 0.4% of both GEODON and placebo patients. During long-term therapy with GEODON, a categorization of patients at baseline on the basis of body mass index (BMI) showed the greatest mean weight gain and the highest incidence of clinically significant weight gain (>7% of body weight) in patients with a low BMI (<23) compared to normal (23-27) or overweight (>27) patients. There was a mean weight gain of 1.4 kg for patients with a "low" baseline BMI, 0.0 kg for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients with a "high" BMI. ***ECG Changes:*** GEODON is associated with an increase in the QT_c interval (see **WARNINGS**). In schizophrenia trials, GEODON was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. ***Other Adverse Events Observed During the Premarketing Evaluation of GEODON:*** Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Schizophrenia: Body as a Whole—*Frequent:* abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. Cardiovascular System—*Frequent:* tachycardia, hypertension, postural hypotension; *Infrequent:* bradycardia, angina pectoris, atrial fibrillation; *Rare:* first-degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis. Digestive System—*Frequent:* anorexia, vomiting; *Infrequent:* rectal hemorrhage, dysphagia, tongue edema; *Rare:* gum hemorrhage, jaundice, fecal impaction, gamma glutamyl transpeptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena. Endocrine—*Rare:* hypothyroidism, hyperthyroidism, thyroiditis. Hemic and Lymphatic System—*Infrequent:* anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy; *Rare:* thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia. Metabolic and Nutritional Disorders—*Infrequent:* thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia; *Rare:* BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis. Musculoskeletal System—*Frequent:* myalgia; *Infrequent:* tenosynovitis; *Rare:* myopathy. Nervous System—*Frequent:* agitation, extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy; *Infrequent:* paralysis; *Rare:* myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System—*Frequent:* dyspnea; *Infrequent:* pneumonia, epistaxis; *Rare:* hemoptysis, laryngismus. Skin and Appendages—*Infrequent:* maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses—*Frequent:* fungal dermatitis; *Infrequent:* conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia; *Rare:* eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. Urogenital System—*Infrequent:* impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; *Rare:* gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. **Adverse Finding Observed in Trials of Intramuscular GEODON:** In these studies, the most commonly observed adverse events associated with the use of intramuscular GEODON (≥5%) and observed at a rate on intramuscular GEODON (in the higher dose groups) at least twice that of the lowest intramuscular GEODON group were headache (13%), nausea (12%), and somnolence (20%). **Adverse Events at an Incidence >1% in Short-Term Fixed-Dose Intramuscular Trials:** The following list enumerates the treatment-emergent adverse events that occurred in ≥1% of GEODON patients (in the higher dose groups) and at least twice that of the lowest intramuscular GEODON group. Body as a Whole—headache, injection site pain, asthenia, abdominal pain, flu syndrome, back pain. Cardiovascular—postural hypotension, hypertension, bradycardia, vasodilation. Digestive—nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous—dizziness, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. Respiratory—rhinitis. Skin and Appendages—furunculosis, sweating. Urogenital—dysmenorrhea, priapism. **DRUG ABUSE AND DEPENDENCE—*Controlled Substance Class:*** GEODON is not a controlled substance. **OVERDOSAGE**—In premarketing trials in over 5400 patients, accidental or intentional overdosage of GEODON was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (BP 200/75).

References: 1. Data on file. Pfizer Inc., New York, NY. **2.** Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K, and the Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. *Am J Psychiatry*. 2003;160:741-748.

Rev. 5 April 2005

GZ259079A

© 2005 Pfizer Inc. All rights reserved.

Pfizer U.S. Pharmaceuticals

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Plastic Surgery Addiction

Continued from page 79

Patients who are dissatisfied with their operations feel guilty and angry with themselves or the surgeon for not making their appearance better, or in some cases, for making it worse. Men with BDD who received plastic surgery tend to direct their anger at the surgeon (Phillips, 2001). Nevertheless, even after "unsuccessful" procedures, BDD sufferers continue getting repeated plastic surgeries in pursuit of correcting their perceived ugliness. Ironically, all of those people would be considered of above-average attractiveness.

The average time frame to diagnosis for BDD is 10 to 15 years after onset, due in part to the secretiveness of patients about their preoccupation, but also due to inadequate training and experience in diagnosing BDD for internists, dermatologists, plastic surgeons and even health care professionals (Sarwer et al., 2003). Body dysmorphic disorder is considered a significantly more difficult and complicated disorder than any other anxiety disorder due to the attendant delusion and distortions, which can cause clinical depression accompanied, in more than 80% of the cases, with suicidal ideation (Phillips, 1998; Phillips et al., 2004). In 20% of the cases, completed suicide results in the endangered lives of about 1 million Americans.

The course of the illness starts at around age 18, oftentimes during the first year of college. Onset can be sparked by drastic changes in one's life. Body dysmorphic disorder may be as significant as chronic depression, social phobia or substance abuse, all three of which can be secondary to BDD (Phillips, 2001). Patients with BDD are often misdiagnosed with having substance abuse disorders or depression.

Challenges of Treating an Image Disorder

Current successful treatments for BDD include cognitive-behavioral therapy (CBT) and medication (selective serotonin reuptake inhibitors or clomipramine [Klonopin]) (Patterson et al., 2003; Slaughter and Sun, 1999). Due to their recent development, these treatments are only beginning to show signs of effectiveness. Although some studies indicate different degrees of success of medication treatment for BDD, CBT still should be considered. The greatest challenge is convincing patients their condition is a result of distorted mental imagery. When patients accept a referral to a mental health care professional and receive medication only, 58% of patients show partial or complete symptom resolution (Patterson et al., 2003). It is often the combination of medication and CBT that brings the best results (Neziroglu and Yaryura-Tobias, 1997).

At the beginning of treatment, patients face several significant challenges. First, patients need to be educated about the nature and course of BDD. Second, patients often have difficulty coping with their disease and the fear related to the beliefs and rituals arising from their preoccupation (Phillips, 2001). Self-esteem needs to be addressed due to the fact that BDD sufferers have distorted vision of themselves. Finally, patients often have to deal with family members and health care professionals who lack understanding or knowledge regarding the extent of BDD.

> In the United States, BDD affects about 2% of the population ... which is equivalent to 5 million Americans and strikes males and females equally.

Patients with BDD are a particular challenge to CBT practitioners. Patients suffer from a body image distortion that is internalized through social factors (such as peer pressure and parental critique) and an as yet undefined neurological deficit (Slaughter and Sun, 1999). The internalized perception prompts them to ritualize their behavior by constantly checking the problem part in mirrors and reflective surfaces. It is difficult for a mental health care practitioner to habituate such a patient to the internalized irrational stimuli. Exposure to external referents is usually preferable. Because each patient with BDD is concerned about different body parts, individually tailored treatments are required. Such a task requires highly developed skills and intuition.

'Crooked Mirrors': a New Treatment Method

Recently a new standardized treatment technique has been developed and adopted by the Westwood Institute for Anxiety Disorders. The method involves the use of distorted mirrors to counter the false beliefs and ritualistic obsessions associated with BDD. A set of distorted mirrors made from highly reflective (anodized) aluminum surfaces bent in different directions are practical in clinical settings because they are inexpensive, easily concealed behind curtains and occupy little space.

The theoretical underpinnings of our method, which we call "externalization therapy," are the time-tested ideas of exposure and response prevention that work so well in treating OCD and posttraumatic stress disorder (Foa, 1996; Foa and Kozak, 1986). The typical exposure involves the guided controlled introduction of the internal irrational stimuli—and this is the basic BDD paradox. The patient believes that their defect is real and visible. The therapist does not see it and does not agree that the defect exists. Maybe it is real and then maybe it is not. What matters is what patients with BDD "do" with their belief. And what they do is truly fascinating: the internalized (mis)perception prompts these patients to ritualize their behavior by either constantly checking the "problem part" in the mirrors and reflective surfaces or by avoiding mirrors altogether. Either strategy results in major levels of distress and anxiety. It would be counterproductive for a mental health practitioner to habituate such a patient by exposure to the internalized irrational stimuli for then anxiety would only increase further. Exposure to external referents thus becomes the only choice.

By using mirrors that grotesquely distort the patient's "real" image, we reverse the process of habituation. Through exposure to the exaggeratedly distorted image, patients externalize reactions to their own physical deformity. The key is in the gradual initiation of outside processes through which patient gains control of concurrent anxiety. The therapist's role is to teach patients how to control this anxiety when they face their distorted images in the crooked mirrors. Gradually, patients habituate to the anxiety present when they are faced with the "ugly" part of their body for it is not the "ugliness" that is being attacked but the "shame." Exposures are done in a gradual hierarchical order starting with the least difficult one and moving up to the most feared one.

This distorted mirror exposure intervention involves 15, 90-minute therapy sessions. While the small sample size does not allow for any significant generalizations regarding efficacy, five of the seven treated patients with BDD improved. One of the two patients failed to demonstrate treatment gains, whereas the second nonresponder is still receiving services.

A successful case involved a 45-year-old female with BDD who had 17 plastic surgeries prior to participating in this distorted mirror exposure (Gorbis, 2003). She had not responded to several prior treatments for OCD and BDD, including a variety of SSRIs. The patient was demoralized because her condition had persisted for many years, and she met criteria for severe BDD and OCD. She scored 32 on the Yale-Brown Obsessive-Compulsive Scale for Body Dysmorphic Disorder (BDD-YBOCS).

The patient was afraid of getting old, looking ugly and being imperfect. She established rituals in an effort to protect herself from aging and becoming ugly. She performed 20 to 30 facial wraps a day, washed her face 40 times daily, scrutinized the symmetry of her body parts, put cosmetics on in a particular order, and frequently looked into mirrors seeking reassurance that she was attractive. Her facial rubs and other rituals of perfection required more than eight hours. In one instance she missed her 35th birthday party and appeared at the party location 32 hours later because she was so absorbed in perfecting the look of her face.

During treatment she was exposed to the distorted mirrors, instructed to wear mismatching jewelry and clothes, and put makeup on one eye but not the other. The distorted mirrors exaggerated her perceived imperfections. By the end of treatment, scores on the BDD-YBOCS had decreased from 32 to 10. Five-year follow-up revealed that she had not undergone any further surgeries.

Distorted mirrors were used to assist three additional patients in understanding the exaggerated nature of their perceived imperfections. One patient had undergone two plastic surgeries and, like most others with BDD, was not satisfied with the results. Another patient never had plastic surgery, but did need a number of surgeries to reconstruct body parts that were destroyed and distorted by her obsessive-compulsive behavior (e.g., obsessively working out to the point of injury). The last patient was treated before having plastic surgery. In total, patients exposed to the distorted mirror intervention initially obtained an average score of 33 on the BDD-YBOCS scale and an average score of 7.29 at termination. Follow-up interviews conducted with patients who were successfully treated revealed no posttreatment plastic surgery.

Conclusion

In our social and cultural environment that focuses solely on external beauty without any regard to our self-worth, society solidifies obsession with appearance. The lack of cooperation from plastic surgeons, lack of information available to the general public and lack of knowledge about BDD exhibited by the medical community may contribute to the 20% suicide rate among sufferers of BDD.

It is our goal to make the initial signs of BDD recognizable to the public and make sure that differential diagnoses and referrals are made properly and appropriately by physicians. Statistics show that 5 million Americans are afflicted by BDD, but at this point we can recognize the sufferers only due to the actual manifestation of this disease,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

which is plastic surgery. This means that only people with financial means to afford plastic surgery are becoming visible. Although we do not know the exact statistics yet as studies are still in progress, it is our suspicion that there are millions of people who suffer with BDD.

Dr. Gorbis is a founder of the Westwood Institute for Anxiety Disorders in Los Angeles and a member of the scientific advisory board for the Obsessive-Compulsive Foundation.

Ms. Kholodenko has a BA in psychology from the University of California, Los Angeles. She is planning to study anxiety disorders for her graduate career.

References

Albertini RS, Phillips KA (1999), Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 38(4):453-459.

American Society for Dermatologic Surgery (undated), Exaggerations about cosmetic flaws linked with mental illness. Available at: www.cosmeticsurgery-news.com/article2313.html. Accessed June 6, 2005.

Foa EB (1996), The efficacy of behavioral therapy with obsessive-compulsives. The Clinical Psychologist 49(2):19-22.

Foa EB, Kozak MJ (1986), Emotional processing of fear: exposure to corrective information. Psychol Bull 99(1):20-35.

Gorbis EE (2003), Addiction to plastic surgeries in patients with BDD. Symposium No. 63D. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco; May 17-22.

Knorr NJ, Edgerton MT, Hoopes JE (1967), The "insatiable" cosmetic surgery patient. Plast Reconstr Surg 40(3):285-289.

Neziroglu F, Yaryura-Tobias JA (1997), A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder. Behav Modif 21(3):324-340.

Patterson WM, Bienvenu OJ, Chodynicki MP et al. (2003), Dysmorphophobia. eMedicine. Available at: www.emedicine.com/derm/topic623.htm. Accessed July 28, 2005.

Phillips KA (1998), Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin 62(4 suppl A):A33-A48.

Phillips KA (2001), Body dysmorphic disorder. In: Somatoform and Factitious Disorders, Phillips KA, ed. (Review of Psychiatry Series, Vol. 20 No. 3, Oldham JM, Riba MD, series editors). Washington, D.C.: American Psychiatric Publishing, pp67-94.

Phillips KA, Castle DJ (2001), Somatoform disorders: a topic for education. Br J Psychiatry 179:465-466 [letter].

Phillips KA, Diaz SF (1997), Gender differences in body dysmorphic disorder. J Nerv Ment Dis 185(9):570-577.

Phillips KA, Dufresne RG, Wilkel CS et al. (2000), Rate of body dysmorphic disorder in dermatology patients. J Am Acad Dermatol 42(3):436-441.

Phillips KA, Grant J, Siniscalchi J, Albertini RS (2001), Surgical and nonpsychiatric medical treatment of patients with body dysmorphic disorder. Psychosomatics 42(6):504-510.

Phillips KA, McElroy SL, Keck PE Jr et al. (1993), Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 150(2):302-308 [see comments].

Phillips KA, Siniscalchi JM, McElroy SL (2004), Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q 75(4):309-320.

Sarwer DB, LaRossa D, Bartlett SP et al. (2003), Body image concerns of breast augmentation patients. Plast Reconstr Surg 112(1):83-90.

Slaughter JR, Sun AM (1999), In pursuit of perfection: a primary care physician's guide to body dysmorphic disorder. Am Fam Physician 60(6):1738-1742.

Veale D (2000), Outcome of cosmetic surgery and 'DIY' surgery in patients with body dysmorphic disorder. Psychiatric Bulletin 24(6):218-220.

Watkins CE (2004), Body dysmorphic disorder. Available at: www.ncpamd.com/body_dysmorphic_disorder.htm. Accessed June 21, 2005. ❐

Call for 2006 Special Report Proposals

Psychiatric Times' editors announce the following Special Reports for 2006:

- **January:** Substance Abuse
- **February:** Schizophrenia
- **March:** Anxiety Disorders
- **April:** Neuropsychiatry
- **April Special Edition:** Psychosomatic Medicine
- **May:** Clinical Psychopharmacology
- **June:** Stress
- **July:** Personality Disorder
- **August:** Bipolar Disorder
- **September:** Depression
- **October:** Child & Adolescent Psychiatry
- **October Special Edition:** Treatment Resistance
- **November:** Geriatric Psychiatry
- **December:** Ethnicity, Culture & Race

Please mail proposals, with first two pages of curriculum vitae and list of published works, to: Managing Editor, Psychiatric Times, 2801 McGaw Ave., Irvine, CA 92614 or to: editor@psychiatrictimes.com. ❐

CME cordially invites YOU to attend

Transitioning ADHD Into Adulthood:

Diagnostic and Treatment Implications

Who Will Benefit

The ***U.S. Psychiatric & Mental Health Congress*** is a collaborative summit designed to benefit **all healthcare clinicians** who want to improve their skills and advance their knowledge of mental health.

Educational Objectives

By actively participating in this symposium, attendees will be able to better understand ADHD in adults and recognize diagnosis and treatment strategies that are useful in the management of adults with ADHD.

You must register for the ***2005 U.S. Psychiatric & Mental Health Congress*** in order to attend this symposium. To register for ***Psychiatric Congress***, November 7-10, or for more information, visit **www.psychcongress.com** or call **(800) 447-4474** or **(949) 250-1008**.

Accreditation

CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

CME LLC reserves the right to cancel this program or make necessary changes in speakers, prices, content and other details without notice. CME LLC reserves the right to refuse service to anyone. CME LLC and Eli Lilly and Company are not responsible for any speaker's or registrant's statements, materials, acts or omissions. CME LLC reserves the right to photograph speakers and participants for promotional purposes.

©2005 CME LLC 16223

Las Vegas

Mandalay Bay Resort & Casino

Tuesday, November 8, 2005

9:30-10:45 a.m.

Session 22-0 • 1.25 CME Credits

Program Faculty

David A. Baron, DO, MSEd
Temple

Matthew A. Menza, MD
Robert Wood Johnson Medical School

This program is supported in part by an *unrestricted* educational grant from Eli Lilly and Company.

18th Annual U.S. Psychiatric & Mental Health Congress Conference and Exhibition

Sponsored by CME Continuing Medical Education

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.